Marker sequences for obesity and use of same

摘要

Use of a marker sequence for the diagnosis of adiposity, is claimed, where the marker sequence of a peptide comprising sequences of SEQ ID NO. 1-26 (comprising one of 26 fully defined 147-1076 amino acid sequences, as given in the specification) and/or SEQ ID NO. 1a to 26a (where the sequences are not defined) or their coding cDNA, partial sequence and/or fragments in or from a patient to be examined, is determined. Independent claims are included for: (1) a method for diagnosis of adiposity comprising applying the marker sequences, contacting with body fluid or tissue extract of the patient and detecting the interaction of the body fluid or tissue extract with the marker sequences; (2) a method for stratifying, preferably for risk stratification, or therapy control of patients with adiposity; (3) an array of marker sequences comprising the marker sequence of the peptide comprising sequences of SEQ ID NO. 1-26 and/or SEQ ID NO.1a-26a or their coding cDNA; (4) an assay, protein biochip comprising the array, where the marker sequences are applied on a solid support; (5) use of the array or assay for identifying and characterizing a substance for adiposity comprising an agent for detecting binding success, where the array or assay is contacted with at least a substance to be tested and detecting the binding success; and (6) a target for the treatment and therapy of adiposity.